Reviva's Q3 2024 Results: Brilaroxazine's Potential and Strategic Moves
Thursday, Nov 14, 2024 5:32 pm ET
3min read Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) recently reported its financial results for the third quarter ended September 30, 2024, and highlighted recent business developments. The company's late-stage brilaroxazine program continues to advance, with promising results in the treatment of schizophrenia and expansion potential across other indications.
Reviva reported a net loss of approximately $8.4 million, or $0.25 per share, for the three months ended September 30, 2024, compared to a net loss of approximately $11.3 million, or $0.48 per share, for the same period in 2023. The company's cash totaled approximately $12.0 million as of March 31, 2024, indicating financial stability for ongoing development.
The company's global 1-year open-label extension (OLE) trial is progressing well, with over 100 patients completing one year of treatment. This trial is a key requirement for New Drug Application (NDA) submission, and topline data is expected in December 2024. Additionally, positive vocal biomarker speech latency data from the RECOVER trial further supports brilaroxazine's efficacy in treating negative symptoms and other key symptom domains of schizophrenia.
Reviva's strategic initiatives, such as the expansion of its intellectual property portfolio and the initiation of the registrational Phase 3 RECOVER-2 trial in Q1 2025, subject to additional financing, align with its growth strategy in the schizophrenia market. The company's commitment to addressing unmet medical needs and capitalizing on emerging opportunities is evident in its recent patent grants for brilaroxazine's use in treating idiopathic pulmonary fibrosis (IPF) and pulmonary hypertension (PH).
The completion of the 1-year OLE trial and its topline data in December 2024 will contribute to Reviva's NDA submission for brilaroxazine in schizophrenia. The positive vocal biomarker speech latency data from the RECOVER trial supports brilaroxazine's efficacy in treating negative symptoms and other key symptom domains of schizophrenia, further bolstering the evidence for its potential as a treatment.
In conclusion, Reviva's Q3 2024 financial results reflect the company's continued investment in its late-stage brilaroxazine program. The completion of the 1-year OLE trial and the positive vocal biomarker data support brilaroxazine's potential as a treatment for schizophrenia. Reviva's strategic initiatives, such as the expansion of its intellectual property portfolio and the initiation of the registrational Phase 3 RECOVER-2 trial, align with its growth strategy in the schizophrenia market. Despite the net loss, Reviva's cash total and ongoing development indicate a positive outlook for the company's future.
Reviva reported a net loss of approximately $8.4 million, or $0.25 per share, for the three months ended September 30, 2024, compared to a net loss of approximately $11.3 million, or $0.48 per share, for the same period in 2023. The company's cash totaled approximately $12.0 million as of March 31, 2024, indicating financial stability for ongoing development.
The company's global 1-year open-label extension (OLE) trial is progressing well, with over 100 patients completing one year of treatment. This trial is a key requirement for New Drug Application (NDA) submission, and topline data is expected in December 2024. Additionally, positive vocal biomarker speech latency data from the RECOVER trial further supports brilaroxazine's efficacy in treating negative symptoms and other key symptom domains of schizophrenia.
Reviva's strategic initiatives, such as the expansion of its intellectual property portfolio and the initiation of the registrational Phase 3 RECOVER-2 trial in Q1 2025, subject to additional financing, align with its growth strategy in the schizophrenia market. The company's commitment to addressing unmet medical needs and capitalizing on emerging opportunities is evident in its recent patent grants for brilaroxazine's use in treating idiopathic pulmonary fibrosis (IPF) and pulmonary hypertension (PH).
The completion of the 1-year OLE trial and its topline data in December 2024 will contribute to Reviva's NDA submission for brilaroxazine in schizophrenia. The positive vocal biomarker speech latency data from the RECOVER trial supports brilaroxazine's efficacy in treating negative symptoms and other key symptom domains of schizophrenia, further bolstering the evidence for its potential as a treatment.
RVPH ROE(Average) YoY, ROE(Average)
In conclusion, Reviva's Q3 2024 financial results reflect the company's continued investment in its late-stage brilaroxazine program. The completion of the 1-year OLE trial and the positive vocal biomarker data support brilaroxazine's potential as a treatment for schizophrenia. Reviva's strategic initiatives, such as the expansion of its intellectual property portfolio and the initiation of the registrational Phase 3 RECOVER-2 trial, align with its growth strategy in the schizophrenia market. Despite the net loss, Reviva's cash total and ongoing development indicate a positive outlook for the company's future.
_cbf77e8c1748017079428.jpeg)
